To decipher whether ribosome biogenesis factors, and in particular the rRNA methyltransferase FBL, could be exploited as a novel biomarker to identify breast cancer patients with the poorest outcome at an early stage diagnosis, we first analyzed the association between FBL mRNA expression and overall survival (OS) or disease-free survival (DFS) in a series of 216 breast tumors (TTBD series, Supplementary Table S1). This evidence concerns the gene FBL and breast carcinoma.